Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Malignant Tumor Clear all
Completed Phase 1 Interventional

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

NCT06894771
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
MK-4700, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Hackensack, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

NCT00634634
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sorafenib, Letrozole
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

NCT00121134
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Cyclophosphamide, Methotrexate, Capecitabine
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Jun 10, 2026, 1:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

NCT02311933
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
561
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 1Phase 2 Interventional

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

NCT00031278
View directory record Official record
Conditions
Carcinoma, Metastatic Breast
Interventions
CPG 7909, Herceptin®
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
8
States / cities
Farmington, Connecticut • Plantation, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Fat, Eicosanoids and Breast Cancer Risk

NCT01824498
View directory record Official record
Conditions
Breast Cancer
Interventions
Low Fat diet, Low Fat high n3 diet, High Fat Diet
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
40 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer

NCT00107484
View directory record Official record
Conditions
Breast Cancer
Interventions
ferumoxtran-10, magnetic resonance imaging, sentinel lymph node biopsy
Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2010 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer

NCT00807781
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Mammaglobin-A DNA vaccine
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Jun 10, 2026, 1:55 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

NCT02018419
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
AlloStim, Cryoablation
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

NCT03499899
View directory record Official record
Conditions
Triple-negative Breast Cancer
Interventions
LAG525, PDR001, Carboplatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chandler, Arizona • Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jun 10, 2026, 1:55 AM EDT
Active, not recruiting Not applicable Interventional

Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study

NCT05327452
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Supervised Home-Based Exercise, Unsupervised Home-Based Exercise, Attention Control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jun 10, 2026, 1:55 AM EDT
Withdrawn Not applicable Interventional

Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography

NCT03266562
View directory record Official record
Conditions
Breast Neoplasm
Interventions
F-18 FES, F-18 FDG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577
View directory record Official record
Conditions
Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions
177Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Not applicable Interventional

Second Echelon Node Study With Methylene Blue

NCT01823172
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Methylene blue dye injection of sentinel lymph node
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

NCT00930930
View directory record Official record
Conditions
Breast Cancer
Interventions
cisplatin, everolimus, paclitaxel, placebo, Venous blood draw
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Birmingham, Alabama • Jackson, Mississippi • Hershey, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Jun 10, 2026, 1:55 AM EDT
Suspended Phase 2Phase 3 Interventional

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

NCT03077841
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Terminated Phase 1 Interventional Results available

Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer

NCT03237572
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, High-intensity focused ultrasound (HIFU)
Drug · Device
Lead sponsor
Patrick Dillon, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

A Study of PRT1419 in Patients With Advanced Solid Tumors

NCT04837677
View directory record Official record
Conditions
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
Interventions
PRT1419
Drug
Lead sponsor
Prelude Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jun 10, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Belzutifan, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Recruiting Phase 1 Interventional

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

NCT06430541
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Terminated No phase listed Observational

Role of Beta-Endorphin in Cancer Therapy Fatigue

NCT01113905
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jun 10, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

NSAID Effects on Clinical and Imaging Breast Biomarkers

NCT01761877
View directory record Official record
Conditions
Inflammation, Cancer, Pain, Hypertension
Interventions
Sulindac
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
Up to 75 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Tucson, Arizona • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jun 10, 2026, 1:55 AM EDT